Recent study titled, "Viral Vector and Plasmid DNA Manufacturing Market (By Type: Lentivirus, Adenovirus, Plasmid DNA, Adeno-Associated Virus; By Application: Gene Therapy, Vaccinology; By Disease: Infectious Disease, Genetic Disorders, Cancer; By End Use: Research Institutes, Biotech Companies) – Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 – 2026" which covers detailed statistical analysis and enlightens market dynamics and trends that provide a holistic picture of the industry.
The Global Viral Vector and Plasmid DNA Manufacturing Market size is estimated to grow at CAGR above 21.4 % over the forecast time frame 2019-2026 and reach the market value around USD 1.8 billion by 2026.
Free Download Sample Report Pages for Better Understanding@ https://www.acumenresearchandconsulting.com/request-sample/1335
The market for viral vector and plasmid DNA in the forecast period should be increased by the prevalence and incidence of genetic disorders, infectious diseases, and cancer high unmet needs of rare disorders patients and increasing acceptability of relatively newer treatment alternatives in emerging economies. According to Cancer Research UK, there were 17 million new cases of breast, lung, bowel, prostate cancer in 2018 and four most common cancers in the world, accounting for about 43% of new cases.
In the application of gene therapy, viral vector and plasmid DNA production is used to diagnose patients and treat diseases. High cancer prevalence is projected to boost demand for gene therapy, which will in turn drive market growth. In 2012, cancer is the world’s second largest source of morbidity and death, with around 14 million new cases reported in 2012 and 8.8 million deaths reported in 2015 around the world. In addition, WHO stated that by the end of 2030, the number of new cancer cases should increase by about 70 %
In addition, increased research and development activities in the field of the manufacture of viral vectors and plasmid DNA will in the near future boost its demand. In April 2017, for example, Transgene announced plans for the launch of the research collaboration on TG4010 as an advanced non-scrooky, not-small cell lung cancer (NSCLC) treatment for patients with standard chemical therapy (SCT) in combination with Bristol-Myers Squibb’s Opdivo (nivolumab).
View Detail Information with Complete TOC@ https://www.acumenresearchandconsulting.com/viral-vector-and-plasmid-dna-manufacturing-market
Because of its large use in the manufacture of viral vectors as much as DNA based vaccines, Plasmid DNA sector dominates the global market.
Plasmid DNA is a very attractive part of the global manufacturing market for viral vectors and plasmid DNAs, which is followed by Adeno Associated Viruses (AAV). This is due to the extensive use in the manufacture of various viral vectors of plasmid DNA as the raw material. In addition to the conventional vaccines, various studies have highlighted the benefits of DNA-based vaccines. Due to the various benefits offered by AAV over other vectors, the Adeno-associated Virus segment is likely to enlarge in a significant CAGR over the forecast time period, making them the vector of choice for different clinical studies.
North America dominates the global market
Geographically, five major regions were segmented in the global viral vector and plasmid DNA manufacturing market: North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Because of the large patient pool, technological progress, and high acceptance of advanced treatments in the region, North America dominates the global viral vector and plasmid DNA manufacturing industry. During the forecast period, the region is estimated to remain dominant. Additional factors that are expected to boost the viral vector and plasma DNA manufacturing market in the next few years are the increased medical expenditure, availability of approved gene therapy and increased investment.
Browse All official Market Research Reports Press Releases@ https://www.acumenresearchandconsulting.com/press-releases
Asia Pacific is projected to expand on the viral vector and plasmid DNA manufacturing market in a remarkably large CAGR because of the growing awareness of viral vector – based products in developing countries and the increased research initiatives in countries such as China and Japan.
Key Players & Strategies
The Viral Vector and Plasmid DNA Manufacturing market is consolidated with large number of manufacturers. Key players expand their product portfolios via mergers, acquisitions and partnerships, which is expected to increase the availability of products and therefore to boost the market.
The key players of the market are CobraBiologics, Novasep, Spark Therapeutics, Inc., FUJIFILM Diosynth Ltd, Cell and Gene Therapy Catapult, Kaneka Eurogentec, Inc. Merck KGaA, Lonza and UniQure N.V. and others.
Explore Our Market Blog@ https://www.acumenresearchandconsulting.com/blogs
TABLE OF CONTENT
CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
1.1.1. Definition of Viral Vector & Plasmid DNA Manufacturing
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Viral Vector & Plasmid DNA Manufacturing Market By Type
1.2.2.1. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.2.2. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue Share By Type in 2017
1.2.2.3. Lentivirus
1.2.2.4. Adenovirus
1.2.2.5. Plasmid DNA
1.2.2.6. Adeno-Associated Virus
1.2.2.7. Others
1.2.3. Viral Vector & Plasmid DNA Manufacturing Market By Application
1.2.3.1. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate Comparison By Application (2015-2026)
1.2.3.2. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue Share By Application in 2017
1.2.3.3. Gene Therapy
1.2.3.4. Vaccinology
1.2.3.5. Others
1.2.4. Viral Vector & Plasmid DNA Manufacturing Market By Disease
1.2.4.1. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate Comparison By Disease (2015-2026)
1.2.4.2. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue Share By Disease in 2017
1.2.4.3. Infectious Disease
1.2.4.4. Genetic Disorders
1.2.4.5. Cancer
1.2.4.6. Others
1.2.5. Viral Vector & Plasmid DNA Manufacturing Market By End Use
1.2.5.1. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate Comparison By End Use (2015-2026)
1.2.5.2. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue Share By End Use in 2017
1.2.5.3. Research Institutes
1.2.5.4. Biotech Companies
1.2.5.5. Others
1.2.6. Viral Vector & Plasmid DNA Manufacturing Market by Geography
1.2.6.1. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.6.2. North America Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate (2015-2026)
1.2.6.3. Europe Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate (2015-2026)
1.2.6.4. Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate (2015-2026)
1.2.6.5. Latin America Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate (2015-2026)
1.2.6.6. Middle East and Africa (MEA) Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate (2015-2026)
1.1.1. Definition of Viral Vector & Plasmid DNA Manufacturing
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Viral Vector & Plasmid DNA Manufacturing Market By Type
1.2.2.1. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.2.2. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue Share By Type in 2017
1.2.2.3. Lentivirus
1.2.2.4. Adenovirus
1.2.2.5. Plasmid DNA
1.2.2.6. Adeno-Associated Virus
1.2.2.7. Others
1.2.3. Viral Vector & Plasmid DNA Manufacturing Market By Application
1.2.3.1. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate Comparison By Application (2015-2026)
1.2.3.2. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue Share By Application in 2017
1.2.3.3. Gene Therapy
1.2.3.4. Vaccinology
1.2.3.5. Others
1.2.4. Viral Vector & Plasmid DNA Manufacturing Market By Disease
1.2.4.1. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate Comparison By Disease (2015-2026)
1.2.4.2. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue Share By Disease in 2017
1.2.4.3. Infectious Disease
1.2.4.4. Genetic Disorders
1.2.4.5. Cancer
1.2.4.6. Others
1.2.5. Viral Vector & Plasmid DNA Manufacturing Market By End Use
1.2.5.1. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate Comparison By End Use (2015-2026)
1.2.5.2. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue Share By End Use in 2017
1.2.5.3. Research Institutes
1.2.5.4. Biotech Companies
1.2.5.5. Others
1.2.6. Viral Vector & Plasmid DNA Manufacturing Market by Geography
1.2.6.1. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.6.2. North America Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate (2015-2026)
1.2.6.3. Europe Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate (2015-2026)
1.2.6.4. Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate (2015-2026)
1.2.6.5. Latin America Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate (2015-2026)
1.2.6.6. Middle East and Africa (MEA) Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate (2015-2026)
CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS
2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players
CHAPTER 3. MANUFACTURING PLANTS ANALYSIS
3.1. Capacity and Commercial Production Date of Global Viral Vector & Plasmid DNA Manufacturing Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Viral Vector & Plasmid DNA Manufacturing Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Viral Vector & Plasmid DNA Manufacturing Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Viral Vector & Plasmid DNA Manufacturing Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Viral Vector & Plasmid DNA Manufacturing Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Viral Vector & Plasmid DNA Manufacturing Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Viral Vector & Plasmid DNA Manufacturing Major Manufacturers in 2017
CHAPTER 4. Viral Vector & Plasmid DNA Manufacturing Market By Type
4.1. Global Viral Vector & Plasmid DNA Manufacturing Revenue By Type
4.2. Lentivirus
4.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.3. Adenovirus
4.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.4. Plasmid DNA
4.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.5. Adeno-Associated Virus
4.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.6. Others
4.6.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.2. Lentivirus
4.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.3. Adenovirus
4.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.4. Plasmid DNA
4.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.5. Adeno-Associated Virus
4.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.6. Others
4.6.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
CHAPTER 5. Viral Vector & Plasmid DNA Manufacturing Market By Application
5.1. Global Viral Vector & Plasmid DNA Manufacturing Revenue By Application
5.2. Gene Therapy
5.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.3. Vaccinology
5.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.4. Others
5.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.2. Gene Therapy
5.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.3. Vaccinology
5.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.4. Others
5.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
CHAPTER 6. Viral Vector & Plasmid DNA Manufacturing Market By Disease
6.1. Global Viral Vector & Plasmid DNA Manufacturing Revenue By Disease
6.2. Infectious Disease
6.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.3. Genetic Disorders
6.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.4. Cancer
6.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.5. Others
6.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.2. Infectious Disease
6.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.3. Genetic Disorders
6.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.4. Cancer
6.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.5. Others
6.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
CHAPTER 7. Viral Vector & Plasmid DNA Manufacturing Market By End Use
7.1. Global Viral Vector & Plasmid DNA Manufacturing Revenue By End Use
7.2. Research Institutes
7.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
7.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
7.3. Biotech Companies
7.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
7.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
7.4. Others
7.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
7.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
7.2. Research Institutes
7.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
7.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
7.3. Biotech Companies
7.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
7.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
7.4. Others
7.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
7.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
CHAPTER 8. North America Viral Vector & Plasmid DNA Manufacturing Market By Country
8.1. North America Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate, 2015 – 2026 ($Million)
8.2. North America Viral Vector & Plasmid DNA Manufacturing Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. U.S.
8.3.1. U.S. Viral Vector & Plasmid DNA Manufacturing Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
8.3.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
8.4. Canada
8.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
8.4.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
8.5. Mexico
8.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
8.5.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
8.2. North America Viral Vector & Plasmid DNA Manufacturing Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. U.S.
8.3.1. U.S. Viral Vector & Plasmid DNA Manufacturing Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
8.3.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
8.4. Canada
8.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
8.4.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
8.5. Mexico
8.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
8.5.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
CHAPTER 9. Europe Viral Vector & Plasmid DNA Manufacturing Market By Country
9.1. Europe Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate, 2015 – 2026 ($Million)
9.2. Europe Viral Vector & Plasmid DNA Manufacturing Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. UK
9.3.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.3.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
9.4. Germany
9.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.4.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
9.5. France
9.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.5.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
9.6. Spain
9.6.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.6.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
9.7. Rest of Europe
9.7.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.7.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
9.2. Europe Viral Vector & Plasmid DNA Manufacturing Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. UK
9.3.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.3.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
9.4. Germany
9.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.4.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
9.5. France
9.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.5.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
9.6. Spain
9.6.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.6.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
9.7. Rest of Europe
9.7.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.7.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
CHAPTER 10. Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Market By Country
10.1. Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate, 2015 – 2026 ($Million)
10.2. Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. China
10.3.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.3.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
10.4. Japan
10.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.4.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
10.5. India
10.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.5.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
10.6. Australia
10.6.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.6.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
10.7. South Korea
10.7.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.7.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
10.8. Rest of Asia-Pacific
10.8.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.8.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
10.2. Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. China
10.3.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.3.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
10.4. Japan
10.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.4.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
10.5. India
10.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.5.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
10.6. Australia
10.6.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.6.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
10.7. South Korea
10.7.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.7.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
10.8. Rest of Asia-Pacific
10.8.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.8.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
CHAPTER 11. Latin America Viral Vector & Plasmid DNA Manufacturing Market By Country
11.1. Latin America Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate, 2015 – 2026 ($Million)
11.2. Latin America Viral Vector & Plasmid DNA Manufacturing Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Brazil
11.3.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
11.3.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
11.4. Argentina
11.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
11.4.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
11.5. Rest of Latin America
11.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
11.5.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
11.2. Latin America Viral Vector & Plasmid DNA Manufacturing Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Brazil
11.3.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
11.3.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
11.4. Argentina
11.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
11.4.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
11.5. Rest of Latin America
11.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
11.5.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
CHAPTER 12. Middle East Viral Vector & Plasmid DNA Manufacturing Market By Country
12.1. Middle East Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate, 2015 – 2026 ($Million)
12.2. Middle East Viral Vector & Plasmid DNA Manufacturing Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. Saudi Arabia
12.3.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
12.3.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
12.4. UAE
12.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
12.4.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
12.5. Rest of Middle East
12.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
12.5.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
12.2. Middle East Viral Vector & Plasmid DNA Manufacturing Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. Saudi Arabia
12.3.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
12.3.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
12.4. UAE
12.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
12.4.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
12.5. Rest of Middle East
12.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
12.5.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
CHAPTER 13. Africa Viral Vector & Plasmid DNA Manufacturing Market By Country
13.1. Africa Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate, 2015 – 2026 ($Million)
13.2. Africa Viral Vector & Plasmid DNA Manufacturing Market Revenue Share Comparison, 2015 & 2026 (%)
13.3. South Africa
13.3.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
13.3.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
13.4. Egypt
13.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
13.4.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
13.5. Rest of Africa
13.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
13.5.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
13.2. Africa Viral Vector & Plasmid DNA Manufacturing Market Revenue Share Comparison, 2015 & 2026 (%)
13.3. South Africa
13.3.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
13.3.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
13.4. Egypt
13.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
13.4.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
13.5. Rest of Africa
13.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
13.5.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
CHAPTER 14. COMPANY PROFILE
14.1. CobraBiologics
14.1.1. Company Snapshot
14.1.2. Overview
14.1.3. Financial Overview
14.1.4. Product Portfolio
14.1.5. Key Developments
14.1.6. Strategies
14.2. Novasep
14.2.1. Company Snapshot
14.2.2. Overview
14.2.3. Financial Overview
14.2.4. Product Portfolio
14.2.5. Key Developments
14.2.6. Strategies
14.3. Spark Therapeutics, Inc.
14.3.1. Company Snapshot
14.3.2. Overview
14.3.3. Financial Overview
14.3.4. Product Portfolio
14.3.5. Key Developments
14.3.6. Strategies
14.4. FUJIFILM Diosynth Ltd
14.4.1. Company Snapshot
14.4.2. Overview
14.4.3. Financial Overview
14.4.4. Product Portfolio
14.4.5. Key Developments
14.4.6. Strategies
14.5. Cell and Gene Therapy Catapult
14.5.1. Company Snapshot
14.5.2. Overview
14.5.3. Financial Overview
14.5.4. Product Portfolio
14.5.5. Key Developments
14.5.6. Strategies
14.6. Kaneka Eurogentec, Inc.
14.6.1. Company Snapshot
14.6.2. Overview
14.6.3. Financial Overview
14.6.4. Product Portfolio
14.6.5. Key Developments
14.6.6. Strategies
14.7. Merck KGaA
14.7.1. Company Snapshot
14.7.2. Overview
14.7.3. Financial Overview
14.7.4. Product Portfolio
14.7.5. Key Developments
14.7.6. Strategies
14.8. Lonza
14.8.1. Company Snapshot
14.8.2. Overview
14.8.3. Financial Overview
14.8.4. Product Portfolio
14.8.5. Key Developments
14.8.6. Strategies
14.9. UniQure N.V.
14.9.1. Company Snapshot
14.9.2. Overview
14.9.3. Financial Overview
14.9.4. Product Portfolio
14.9.5. Key Developments
14.9.6. Strategies
14.10. Others
14.10.1. Company Snapshot
14.10.2. Overview
14.10.3. Financial Overview
14.10.4. Product Portfolio
14.10.5. Key Developments
14.10.6. Strategies
14.1.1. Company Snapshot
14.1.2. Overview
14.1.3. Financial Overview
14.1.4. Product Portfolio
14.1.5. Key Developments
14.1.6. Strategies
14.2. Novasep
14.2.1. Company Snapshot
14.2.2. Overview
14.2.3. Financial Overview
14.2.4. Product Portfolio
14.2.5. Key Developments
14.2.6. Strategies
14.3. Spark Therapeutics, Inc.
14.3.1. Company Snapshot
14.3.2. Overview
14.3.3. Financial Overview
14.3.4. Product Portfolio
14.3.5. Key Developments
14.3.6. Strategies
14.4. FUJIFILM Diosynth Ltd
14.4.1. Company Snapshot
14.4.2. Overview
14.4.3. Financial Overview
14.4.4. Product Portfolio
14.4.5. Key Developments
14.4.6. Strategies
14.5. Cell and Gene Therapy Catapult
14.5.1. Company Snapshot
14.5.2. Overview
14.5.3. Financial Overview
14.5.4. Product Portfolio
14.5.5. Key Developments
14.5.6. Strategies
14.6. Kaneka Eurogentec, Inc.
14.6.1. Company Snapshot
14.6.2. Overview
14.6.3. Financial Overview
14.6.4. Product Portfolio
14.6.5. Key Developments
14.6.6. Strategies
14.7. Merck KGaA
14.7.1. Company Snapshot
14.7.2. Overview
14.7.3. Financial Overview
14.7.4. Product Portfolio
14.7.5. Key Developments
14.7.6. Strategies
14.8. Lonza
14.8.1. Company Snapshot
14.8.2. Overview
14.8.3. Financial Overview
14.8.4. Product Portfolio
14.8.5. Key Developments
14.8.6. Strategies
14.9. UniQure N.V.
14.9.1. Company Snapshot
14.9.2. Overview
14.9.3. Financial Overview
14.9.4. Product Portfolio
14.9.5. Key Developments
14.9.6. Strategies
14.10. Others
14.10.1. Company Snapshot
14.10.2. Overview
14.10.3. Financial Overview
14.10.4. Product Portfolio
14.10.5. Key Developments
14.10.6. Strategies
CHAPTER 15. RESEARCH APPROACH
15.1. Research Methodology
15.1.1. Initial Data Search
15.1.2. Secondary Research
15.1.3. Primary Research
15.2. Assumptions and Scope
15.1.1. Initial Data Search
15.1.2. Secondary Research
15.1.3. Primary Research
15.2. Assumptions and Scope
Buy this Premium Research Report@ https://www.acumenresearchandconsulting.com/buy-now/0/1335
The report is readily available and can be dispatched immediately after payment confirmation.
Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157
0 Comments
Get More Detail Study, Visit Here: https://www.acumenresearchandconsulting.com/